sar425899 sanofi dual agonist glp-1 glucagon Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current
Description
Four weeks ago, I wrote about my decision to undertake a weight-loss journey using a GLP-1 (a semagl
A lower, fixed dose for those who want a gentle, mindful, cosmetic approach rather than full dose weight loss
Ginfortprovides a natural solution to mitigate these issues
Research on the experimental drug petrelintide suggests it is much less likely to cause nausea and vomiting than GLP-1 drugs, but the pace of weight loss is more moderate.
hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12)
these signals are hypothesis-generating and should not be interpreted as confirmed causal risks
